NIH scientists find a potential new avenue for cancer therapies
Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.
Read more ...
A gene that protects against colorectal cancers
The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.
Read more ...
New light on medicinal benefits of plants
Scientists are about to make publicly available all the data they have so far on the genetic blueprint of medicinal plants and what beneficial properties are encoded by the genes identified.
Read more ...
Blood test might predict how well a depressed patient responds to antidepressants
Loyola University Medical Center researchers are reporting what could become the first reliable method to predict whether an antidepressant will work on a depressed patient. The method would involve a blood test for a protein called vascular endothelial growth factor (VEGF).
Read more ...
Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies?
Consumers hold churches and pharmaceutical companies to different moral standards than other organizations, according to a new study in the Journal of Consumer Research.
Read more ...
Scientists discover new way to target cancer
Scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published in the journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.
Read more ...
Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.
Read more ...
